Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 1999

View Archived Issues

Genzyme General's Seprafilm approved in Europe for cardiac surgery

Growth factors shown to improve muscle healing in animal models

Merck terminates negotiations with Bioject

Biogen and Ontogeny extend hedgehog protein collaboration

Magainin reports interim results of squalamine trial

Two German pharmaceutical companies join forces in urology segment

Millennium Preventive Medicine and Becton Dickinson establish diagnostics alliance

Aurora enters screening agreement with Roche

Novel BK channel modulators developed at Bristol-Myers Squibb

Azacycloalkane derivatives for diabetes and related disorders patented by Synthelabo

Fujisawa's new hypoglycemic and hypolipidemic agents

CNS compounds from Merck acting on serotonergic system

Bayer claims oxazolidinones active against Gram-positive bacteria and mycobacteria

Clinically effective antiarthritic drug offered for licensing by KS Biomedix

Company Profile: Almirall Prodesfarma

New Vasogen technology protects against GVHD in animal model

C5a receptor antagonist with therapeutic potential in endotoxic shock, ARDS

Cubist reports new developments in antibiotic program

Eradication of H. pylori may prevent long-term NSAID-related ulcers

Nevirapine-containing triple combination therapy effective in advanced HIV disease or AIDS

Cortecs concludes phase III Macritonin trial

Matrix begins treating patients in phase II study of FMdC

Muse granted marketing approval in Germany

Rofecoxib up for advisory committee review this spring

InKine schedules pre-NDA meeting with FDA for INKP-100

Zimmer launches Orthovisc in Europe; prepares to begin North American trials

Worldwide strategic alliance established by Agennix and Santen for lactoferrin

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...